Biotech · Private company
Odonate Therapeutics, Inc.
Track this companyFree. Adds Odonate Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- CapecitabinePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Tesetaxel and CapecitabinePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- TesetaxelPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ItraconazolePhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- RifampinPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- TesetaxelPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid TumorsPHASE1 · TERMINATED · started Mar 6, 2020ClinicalTrials.gov NCT04312282 · fetched Nov 12, 2026
- Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBCPHASE2 · TERMINATED · started Jul 9, 2019ClinicalTrials.gov NCT03952325 · fetched Nov 12, 2026
- Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBCPHASE2 · TERMINATED · started Feb 5, 2019ClinicalTrials.gov NCT03858972 · fetched Nov 12, 2026
- Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBCPHASE3 · TERMINATED · started Dec 21, 2017ClinicalTrials.gov NCT03326674 · fetched Nov 12, 2026